Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Atara Biotherap
(NQ:
ATRA
)
0.6328
+0.0088 (+1.41%)
Streaming Delayed Price
Updated: 11:15 AM EDT, May 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Atara Biotherap
< Previous
1
2
3
4
5
Next >
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
May 20, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
May 09, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
March 28, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
February 29, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
February 28, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
February 14, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
January 31, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces $15 Million Registered Direct Offering
January 08, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
December 20, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting
December 11, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023
November 29, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference
November 22, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics To Participate at the Stifel Healthcare Conference
November 10, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis
November 08, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results
November 01, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 06, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability
September 19, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference
August 31, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress
August 08, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
August 01, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
July 31, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 07, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
June 07, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.